Drugs / Lobaplatin
Lobaplatin
Trials 21
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03188497 | Jun 2016 → Dec 2017 | poisoning | Fifth Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 213 trials · 1 missed | ||||||
| Phase 2 | NCT06688175 | Nov 2024 → Dec 2026 expected | nasopharyngeal carcinoma | The First Affiliated Hospital of Xiamen University | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06198465 | Mar → Dec 2024 | esophageal cancer | Xijing Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06586242 | Apr 2023 → Apr 2025 overdue | esophageal cancer | Xijing Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06170697 | Mar 2023 → Jul 2024 | head and neck squamous cell carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT04845490 | Sep 2022 → Sep 2023 overdue | metastasis from malignant tumor of colon | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04808466 | Sep 2021 → Sep 2022 | chemotherapy-induced toxicity, gastric cancer, metastatic neoplasm | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 2 | NCT05546255 | Jun 2020 → Dec 2022 | triple-negative breast carcinoma | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT04273100 | Nov 2019 → Dec 2020 | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03613753 | Jun 2018 → Jun 2020 | small cell lung carcinoma | ShengFa Su | Unknown | No outcome recorded |
| Phase 2 | NCT03613597 | Jun 2018 → Jan 2021 | small cell lung carcinoma | Guizhou Medical University | Unknown | Missed primary |
| Phase 2 | NCT03210389 | Jul 2017 → Dec 2019 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03117257 | Aug 2016 → Aug 2019 | head and neck squamous cell carcinoma | Guiyang Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT01483300 | Nov 2011 → Aug 2014 | breast cancer | Harbin Medical University | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02099396 | Apr 2014 → Jun 2016 | — | China Association of Osteosarcoma Chemotherapy | Unknown | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07417397 | Feb 2026 → Dec 2029 expected | hepatocellular carcinoma | Guangxi Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT05766605 | Jan 2023 → Jan 2026 | hepatocellular carcinoma | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03328234 | Sep 2017 → Aug 2021 | — | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT01034683 | Dec 2009 → Dec 2010 | carcinoma of esophagus | Taian Cancer Hospital | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07093931 | Aug 2025 → Aug 2027 expected | breast cancer | Shandong Cancer Hospital and Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03413436 | Jan → Feb 2018 | esophageal cancer | Henan Cancer Hospital | Completed | No outcome recorded |
| Comparator or background therapy15 trials | ||||||
| Phase 2 | NCT06714383 Background | Nov 2024 → Jul 2025 overdue | conventional osteosarcoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06231680 Background | Jan → Jun 2024 | carcinoma of esophagus, non-small cell lung carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03700359 Background | Mar 2019 → Nov 2020 | small cell lung carcinoma | The First Affiliated Hospital of Guangzhou Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT03048123 Comparator | Oct 2015 → Oct 2016 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT05780294 Comparator | Apr 2023 → Dec 2025 overdue | bone marrow failure syndrome, nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06190782 Background | Sep 2022 → Sep 2025 overdue | esophageal squamous cell carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05701436 Background | Sep 2022 → Jan 2026 | liver cancer | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03791918 Comparator | Jan 2019 → Jan 2022 | hepatocellular carcinoma | Sun Yat-sen University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03731442 Background | Nov 2018 → Oct 2022 overdue | esophageal cancer | Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 3 | NCT03308552 Comparator | Dec 2017 → Aug 2020 | neoplasm of esophagus | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT02973685 Comparator | Oct 2016 → Nov 2020 | hepatocellular carcinoma | Sun Yat-sen University | Completed | Met primary |
| Phase 3 | NCT02856126 Comparator | Aug 2016 → Oct 2020 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02301091 Background | Oct 2014 → Oct 2018 | hepatocellular carcinoma | Ming Zhao | Unknown | No outcome recorded |
| Phase 4 | NCT06169410 Background | Dec 2023 → Dec 2025 | gastric cancer | Yang Jianjun, PhD | Unknown | No outcome recorded |
| — | NCT02678806 Comparator | Nov 2017 → Nov 2018 | hepatocellular carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 38 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lobaplatin | “For patients in the adjuvant TACE group, after superselective catheterization near the hepatic resection margin, embolization will be performed using an emulsion of 50 mg...” NCT07417397 ↗35“Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;” NCT06231680 ↗ “infusion with lipiodol mixed with chemotherapy drugs (EADM , lobaplatin, and MMC ), and embolization with polyvinyl alcohol particles (PVA)” NCT02856126 ↗ “other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.” NCT06190782 ↗ “lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)” NCT03791918 ↗ “Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks” NCT03308552 ↗ “Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks” NCT03328234 ↗ “or TACE (epirubicin 50 mg, lobaplatin 50 mg, and lipiodol and polyvinyl alcohol particles).” PMID 34648352 ↗ Oct 2021 “Then, 50 mg of lobaplatin plus 4 mg of raltitrexed was injected into the vascular artery.” NCT02678806 ↗ “for lobaplatin, 30mg/m2, d1-2, total dose should not exceed 50mg,every 3 weeks” NCT03731442 ↗ “lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC)” NCT03048123 ↗ |
| Known as | LBP | “OBJECTIVES: Lobaplatin (LBP), a third-generation cisplatin derivative has shown promising activity and few side effects in oesophageal squamous cell carcinoma (ESCC) in...” PMID 34589419 ↗ Sep 2021 |
| Known as | Lobaplatine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594256 ↗ |
| Known as | Lobaplatino | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594256 ↗ |
| Known as | NSC-741422 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594256 ↗ |
| Modality | Small molecule | “Lobaplatin is the third generation platinum anticancer drugs” NCT03188497 ↗ |
| Route | Intravenous | “intravenous infusion with lobaplatin 30 mg/m2 for two hours” NCT02099396 ↗ |